Key facts
- Sarmal’s last known valuation is $25.0M (Jan 2026).
- It has raised $8.0M across 1 recorded rounds; the latest was Early Stage VC ($5.0M) in Jun 2025.
- Notable investors include MENE Ventures.
- Sarmal has filed 1 Form D with the SEC, most recently Jan 2026 ($5.0M sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Sarmal
Funding rounds
1 roundsAbout Sarmal
Operator of a DNA technology company intended to develop a sequencing and an advanced target sequence detection system. The company offers whole-genome sequencing technology and a field-deployable nucleic acid-based diagnostic platform, enabling clients to make genetic analysis and molecular testing fast, accessible, and cost-effective.
- Sector
- Healthcare
- HQ
- La Jolla, CA, United States
- Founded
- 2019
- Employees
- 10
- Website
- sarmal.com/
- Ownership
- Privately Held (backing)
Sarmal doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sarmal shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sarmal in its N-PORT filings yet. We sweep new filings monthly.